Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
11β-Hydroxysteroid dehydrogenase type 1 (HSD11B1) is an NADPH-dependent enzyme that catalyzes the conversion of inactive cortisone to active cortisol. It is highly expressed in the liver, adipose tissue, and central nervous system. By regulating local glucocorticoid action, HSD11B1 plays essential roles in carbohydrate metabolism, adipose tissue function, memory processes, blood vessel reactivity, blood pressure regulation, obesity development and osteoporosis risk. Therapeutic inhibition of HSD11B1 is being explored for treating obesity, metabolic syndrome, type 2 diabetes mellitus, and cardiovascular complications. Deficiency states can result from mutations affecting either HSD11B1 itself or hexose‐6‐phosphate dehydrogenase.
Therapeutic inhibition of HSD11B1 to reduce local cortisol levels in metabolic tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD11B1).